The feasibility of adding BV to CHOP in first-line setting was evaluated in a phase 1 study with BV 1.8 mg/kg administered either sequentially with standard-dose CHOP (BV × 2 cycles, followed by CHOP × 6 cycles) or in combination with CHP (CHOP without vincristine) for 6 cycles in patients with mostly CD30-expressing ALCL. Here, TNFRSF8 is linked to anaplastic large cell lymphoma.